NasdaqGS:DYNBiotechs
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise?
Dyne Therapeutics, Inc. recently announced preclinical data showing its FORCE platform can cross the blood-brain barrier and achieve robust MAPT RNA knockdown in the central nervous system in mice and nonhuman primates, using two TfR1-targeting siRNA conjugates that also worked via subcutaneous dosing.
This work suggests Dyne’s clinically validated FORCE platform, originally built for neuromuscular diseases, may be extendable to neurological conditions linked to tau pathology such as...